1. Japan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
FunPep Co., Ltd.

FunPep Co., Ltd.

TTSE:4881
42.00
JPY
-1.00
(-2.33%)
3.09BMarket Cap
Nov 12Next Earn
FunPep Co., Ltd.
TSE:4881
(Tokyo Stock Exchange)

Recent

price

42.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
JPY
6.28
22.08
25.95
0.24
7.36
0.06
0.02
0.22
0.01
- -
Revenue per Share
-12.66
-0.74
-20.25
-40.37
-39.58
-61.04
-39.63
-31.98
-50.2
- -
Basic EPS, GAAP
- -
- -
-29.87
-32.9
- -
-55.51
-42.03
-19.33
-36.45
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
44.45
72.33
57.74
213.09
178.57
125.92
94.97
78.6
36.09
33.06
Book Value per Share
44.35
72.25
57.68
213.05
178.52
102.65
76.05
65.66
35.88
32.9
Tangible Book Value per Share
16
16
12
13
17
19
24
28
38
43
Basic Weighted Avg Shares
101
356
301
3
127
1
1
6
- -
- -
Sales/Revenue/Turnover
-196.05
-4.05
-94.8
-19,010.03
-587.25
-109,565.98
-187,567.36
-14,717.76
-525,053.5
- -
Operating Margin (%)
- -
- -
2
1
- -
14
44
43
42
- -
Depreciation Expense
-204
-12
-235
-508
-682
-1,173
-933
-889
-1,912
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-201.68
-3.35
-78.03
-17,102.02
-537.77
-109,888.94
-176,116.23
-14,511.05
-608,766.56
- -
Profit Margin (%)
709
1,159
922
3,563
3,167
2,298
1,936
2,186
1,418
1,660
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
717
1,166
931
3,569
3,176
2,695
2,302
2,547
1,464
1,675
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-1.27
-22.43
-22.58
-20.23
-39.95
-37.36
-36.67
-95.3
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
26
45
51
Market Capitalization
4,552
3,633
3,091

Working Capital

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
Total Current Assets
2,233
- -
2,094
Cash, Cash Equivalents & STI
1,961
- -
1,895
Accounts Receivable, Net
- -
- -
- -
Inventories
40
- -
15
Total Current Liabilities
433
- -
434
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-14.52%
-42.53%
Free Cash Flow
- -
- -
158.17%
Net Income, GAAP
- -
39.21%
115%
Sales/Revenue/Turnover
- -
996.67%
-94.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
6
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-6.88
-8.11
- -
- -
-31.98
2025
- -
- -
- -
- -
-50.2
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
FunPep Company Limited engages in the research and development of pharmaceuticals, functional cosmetics, and medical devices based on functional peptides. Its core products include functional peptides such as SR-0379 for skin ulcer treatment; antibody-inducing peptides including FPP003, which is in Phase II clinical trials for the treatment of psoriasis in Australia and ankylosing spondylitis in Japan; FPP004X, an antibody-inducing peptide vaccine for pollinosis currently in preclinical trials; FPP006, a corona peptide vaccine; and FPP005, an antibody including peptide for psoriasis. The company also focuses on next-generation formulation technology for antibody-inducing peptides aiming to provide alternatives to expensive antibody drugs and reduce healthcare costs. FunPep operates primarily in Japan but conducts clinical studies internationally, emphasizing unmet medical needs in skin ulcer and autoimmune disease therapeutics. Incorporated in 2013 with headquarters in Tokyo, Japan, FunPep collaborates strategically to advance its pipeline, notably signing a strategic agreement with BIOASTER in March 2025 to optimize an in vitro assay to induce a human B cell immune response for its leading candidates. The company also executed an option agreement with Shionogi regarding an allergy vaccine and has ongoing collaborations to develop antibody-inducing peptide therapies. In 2025, FunPep received ¥3.6 million in funding from SBI Securities and concluded an option agreement with Sumitomo Pharma over the FPP003 peptide, which Sumitomo declined to exercise. These strategic partnerships and funding support FunPep's clinical trials and platform development in functional peptide therapeutics for various chronic and immune-related diseases.